Skip to main content
Log in

Evidence of catecholamine mediation in the ‘Aberrant’ behaviour induced by lysergic acid diethylamide (LSD) in the rat

  • Specialia
  • Studiorum Progressus
  • Published:
Experientia Aims and scope Submit manuscript

Zusammenfassung

Der Einfluss verschiedener Pharmaka auf das durch LSD hervorgerufene bizarre Verhalten der Ratte wurde untersucht. Die Resultate zeigen, dass α- und β-Blocker sowie α-Methyltyrosine eine starke Hemmung dieses Verhaltens erzeugen, im Gegensatz zu den Serotonin-Antagonisten Deseril, BOL-148 und Parachlorphenylalaninen, die nur schwache oder keine Hemmung hervorrufen. Es wird gefolgert, dass das bizarre Verhalten durch Wirkung von LSD an Katecholaminstrukturen hervorgerufen wird. Die Wirkung von 4 psychotropen Pharmaka am bizarren Verhalten wird im Rahmen dieser Hypothese diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. W. A. Stoll, Schweizer Arch. Neurol. Psychiat.60, 279 (1947).

    Google Scholar 

  2. J. H. Gaddum,Ciba Foundation Symposium on Hypertension (Churchill, London 1953).

    Google Scholar 

  3. D. W. Wooley andE. Shaw, Proc. natn. Acad. Sci. USA40, 228 (1954).

    Article  Google Scholar 

  4. D. W. Wooley andE. Shaw, Br. med. J.2, 122 (1954).

    Article  Google Scholar 

  5. F. Rinaldi, L. H. Rudy andH. E. Himwich, Am. J. Psychiat.112, 678 (1956).

    Article  CAS  PubMed  Google Scholar 

  6. A. Cerletti andE. Rothlin, Nature176, 785 (1955).

    Article  CAS  PubMed  Google Scholar 

  7. E. Rothlin, J. Pharm. Pharmac.9, 569 (1957).

    Article  CAS  Google Scholar 

  8. A. Cerletti, inNeuro-Psychopharmacology, First Int. Meet. Neuro-Psychopharmac., Rome 1958 (Eds.P. B. Bradley, P. Deniker andC. Radouco Thomas; Elsevier, Amsterdam 1959), vol. 1, p. 117.

    Google Scholar 

  9. B. B. Brodie, S. Spector andP. A. Shore, Pharmac. Rev.11, 548 (1959).

    CAS  Google Scholar 

  10. E. Costa, G. L. Gessa, C. Hirsch, R. Kuntzman andB. B. Brodie, Ann. N.Y. Acad. Sci.96, 118 (1962).

    Article  CAS  PubMed  Google Scholar 

  11. A. Horita andJ. M. Dille, Science120, 1100 (1954).

    Article  CAS  PubMed  Google Scholar 

  12. A. Horita andJ. H. Gogerty, J. Pharmac. exp. Ther.122, 195 (1958).

    CAS  Google Scholar 

  13. J. H. Gaddum, inSymposium on 5-Hydroxytryptamine (Ed.G. P. Lewis; Pergamon Press, London 1958), p. 195.

    Google Scholar 

  14. V. Erspamer, Archs int. Pharmacodyn. Thér.93, 293 (1953).

    CAS  Google Scholar 

  15. J. H. Gaddum, A. Khan-Hameed, D. E. Hathway andF. F. Stephens, Q. Jl exp. Physiol.40, 49 (1955).

    Article  CAS  Google Scholar 

  16. W. Doepfner, Experientia18, 256 (1962).

    Article  CAS  PubMed  Google Scholar 

  17. M. Taeschler andA. Cerletti, Pharmac. exp. Ther.120, 179 (1957).

    CAS  Google Scholar 

  18. K. Koe andA. Weissman, J. Pharmac. exp. Ther.154, 499 (1966).

    CAS  Google Scholar 

  19. S. Spector, A. Sjoerdsma andS. Udenfriend, J. Pharmac. exp. Ther.147, 86 (1965).

    CAS  Google Scholar 

  20. D. X. Freedman, J. Pharmac. exp. Ther.134, 160 (1961).

    CAS  Google Scholar 

  21. D. X. Freedman, Am. J. Psychiat.119, 843 (1963).

    Article  CAS  PubMed  Google Scholar 

  22. S. A. Rosecrans, R. A. Lovell andD. V. Freedman, Biochem. Pharmac.16, 2011 (1967).

    Article  CAS  Google Scholar 

  23. J. Mussachio, I. J. Kopin andS. Snyder, Life Sci.3, 769 (1964).

    Article  Google Scholar 

  24. M. Goldstein, B. Anagnoste andE. Lauber, Life Sci.3, 763 (1964).

    Article  CAS  Google Scholar 

  25. M. Goldstein, Pharmac. Rev.18, 77 (1966).

    CAS  Google Scholar 

  26. A. Pletscher, M. Da Prada andG. Foglar, 5th Int. Congr. Neuro-psychopharmac. (Excerpta Medica, Amsterdam 1967), p. 101.

    Google Scholar 

  27. J. M. van Rossum, 5th Int. Congr. Neuro-psychopharmac. (Excerpta Medica, Amsterdam 1967), p. 304.

    Google Scholar 

  28. A. Pletscher andM. da Prada, 5th Int. Congr. Neuro-psychopharmac. (Excerpta Medica, Amsterdam 1967), p. 304.

    Google Scholar 

  29. H. Nybaeck, G. Sedvall andI. J. Kopin, Life Sci.6, 2307 (1967).

    Article  Google Scholar 

  30. D. F. Sharman, Br. J. Pharmac. Chemother.28, 153 (1966).

    Article  CAS  Google Scholar 

  31. D. F. Sharman, Br. J. Pharmac. Chemother.30, 620 (1967).

    Article  CAS  Google Scholar 

  32. Z. Votava, S. N. Glisson andH. E. Himwich, Int. J. Neuropharmac.6, 543 (1967).

    Article  CAS  Google Scholar 

  33. J. Glowinski andJ. Axelrod, Pharmac. Rev.18, 775 (1966).

    CAS  Google Scholar 

  34. L. Stjaerne, Acta physiol. scand.62, Suppl. 228 (1964).

  35. L. L. Iversen,Uptake and Storage of Noradrenaline in Sympathetic Nerves (Cambridge Univ. Press. 1967), p. 147.

  36. J. Axelrod, G. Hertting andL. Potter, Nature194, 297 (1962).

    Article  CAS  PubMed  Google Scholar 

  37. F. Sulser andJ. V. Dingell, inAntidepressant Drugs of Non-MAO-Inhibitor type (Proceedings of a Workshop; U.S. Dept. of Health, Education and Welfare 1966).

  38. L. L. Iversen, J. Axelrod andJ. Glowinski, 5th Int. Congr. Neuro-psycho-pharmac. (Excerpta Medica, Amsterdam 1967), p. 326.

    Google Scholar 

  39. J. Glowinski andJ. Axelrod, Nature204, 1318 (1964).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dixon, A.K. Evidence of catecholamine mediation in the ‘Aberrant’ behaviour induced by lysergic acid diethylamide (LSD) in the rat. Experientia 24, 743–747 (1968). https://doi.org/10.1007/BF02138352

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02138352

Keywords

Navigation